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The aetiology of late-onset neurodegenerative diseases is largely unknown. Here we investigated whether de novo somatic variants for se-
mantic dementia can be detected, thereby arguing for a more general role of somatic variants in neurodegenerative disease. Semantic de-
mentia is characterized by a non-familial occurrence, early onset (565 years), focal temporal atrophy and TDP-43 pathology. To test
whether somatic variants in neural progenitor cells during brain development might lead to semantic dementia, we compared deep exome
sequencing data of DNA derived from brain and blood of 16 semantic dementia cases. Somatic variants observed in brain tissue and ab-
sent in blood were validated using amplicon sequencing and digital PCR. We identified two variants in exon one of the TARDBP gene
(L41F and R42H) at low level (1–3%) in cortical regions and in dentate gyrus in two semantic dementia brains, respectively. The patho-
genicity of both variants is supported by demonstrating impaired splicing regulation of TDP-43 and by altered subcellular localization of
the mutant TDP-43 protein. These findings indicate that somatic variants may cause semantic dementia as a non-hereditary neurodegener-
ative disease, which might be exemplary for other late-onset neurodegenerative disorders.
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Introduction
Multifactorial aetiology, including genetic and environmen-
tal factors, has been used to explain most late-onset neuro-
degenerative diseases. Only a small percentage of cases with
autosomal dominant inheritance is caused by germline var-
iants in specific genes, for example PSEN1 and APP variants
in Alzheimer’s disease, MAPT and GRN in frontotemporal
dementia (FTD) and C9orf72 and TARDBP in both
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amyotrophic lateral sclerosis and FTD (Ferrari et al., 2019;
Greaves and Rohrer, 2019; Clarimon et al., 2020). There is
an increasing interest in the potential pathogenic role of de
novo variants in patients with neurodegenerative diseases
with a negative family history (Leija-Salazar et al., 2018;
Lodato and Walsh, 2019). A few cases with de novo germ-
line variants have been identified in early-onset Alzheimer’s
disease (Nicolas et al., 2018). For neurodevelopmental dis-
eases, low-level (420% of cells) somatic variants in mTOR,
AKT3 and CCND arising from the ventricular or subven-
tricular zone have been identified by deep sequencing of can-
didate genes in affected brain tissue (Lee et al., 2012; Lin
et al., 2012; Veltman and Brunner, 2012; Miller et al.,
2013; Poduri et al., 2013; Hu et al., 2014; Jamuar et al.,
2014; Kovacs et al., 2014; Mirzaa et al., 2014; Rogalski
et al., 2014; Bushman et al., 2015; Lim et al., 2015; Lodato
et al., 2015; Sala Frigerio et al., 2015; Wiseman et al., 2015;
Hoekstra et al., 2016; Kim et al., 2016; Takata et al., 2016).
The hypothesis is that post-zygotic variants (after fertiliza-
tion) or late-somatic variants during brain development
might explain the sporadic presentation of neurodegenera-
tive diseases with a negative family history.
The most ideal approach to determine the role of late-
somatic variants in neurodegenerative diseases would be the
comparison between blood- and brain-derived DNA within
the same patients. However, brain tissue for DNA isolation
was often not available during life, and DNA derived from
blood was often not collected during life in deceased
patients. Recent brain-derived DNA studies without matched
DNA samples from blood have tried to detect somatic var-
iants in Alzheimer’s and Parkinson’s disease (Beck et al.,
2004; Lin et al., 2012; Proukakis et al., 2014; Bushman
et al., 2015; Lodato et al., 2015; Sala Frigerio et al., 2015;
Wiseman et al., 2015; Coxhead et al., 2016; Hoekstra et al.,
2016; Lee et al., 2018; Lodato et al., 2018; Mokretar et al.,
2018; Nicolas et al., 2018; Park et al., 2019; Wei et al.,
2019). A higher number of low-level mosaic variants in
causative genes (APP, SNCA) have been detected in DNA of
Alzheimer’s disease or Parkinson’s disease brains compared
to controls (Lee et al., 2018; Mokretar et al., 2018). Only
the study by Park et al. (2019) performing deep sequencing
of hippocampal formation and matched blood tissues found
an enrichment of somatic DNA variation in the Tau signal-
ling pathway in Alzheimer’s disease patients compared to
controls (Park et al., 2019). Specifically, a single carrier of a
somatic variant in PIN1 was suggested as potential causal
factor in the respective Alzheimer’s disease patient (Park
et al., 2019).
In the present study, we uniquely investigated the presence
of low-level somatic variants in the temporal cortex and den-
tate gyrus of brains of patients with semantic dementia,
which were absent in their blood-derived DNA. Semantic de-
mentia is a well-defined clinical and pathological subtype of
FTD, mostly occurring before the age of 65 (Hodges et al.,
1992; Irish et al., 2012; Mesulam et al., 2014). The disease
is characterized by a circumscribed asymmetric atrophy of
the anterior temporal cortex, suggesting a local disease
process (Mummery et al., 2000; Kumfor et al., 2016).
Severe neuronal loss with pathological TDP-43 protein accu-
mulation in neurites and neurons in the temporal cortex and
dentate gyrus of the hippocampus are the defining salient
and consistent neuropathological features of semantic de-
mentia, most commonly classified as FTD-TDP type C
(Davies et al., 2005; Mackenzie et al., 2011; Leyton et al.,
2016; Neumann and Mackenzie, 2019). Semantic dementia
has a sporadic, non-familial occurrence, and a current lack
of mechanistic insight in the disease process precludes a
therapeutic strategy. We performed deep exome sequencing
(310–658 ) of middle temporal gyrus and dentate gyrus
tissue of semantic dementia patients with pathologically con-
firmed FTD-TDP type C, and compared data with blood
DNA samples of the same patients. We identified somatic
TARDBP variants in the brains of two semantic dementia
patients that were absent in blood. These variants were vali-
dated using custom amplicon panel sequencing and digital
droplet PCR. In addition, we confirmed the disruptive effects
of these TARDBP variants by demonstrating altered cellular
distribution of the mutant TDP-43 proteins. Our results indi-
cate that somatic variants in TARDBP contribute to seman-
tic dementia pathogenesis.
Materials and methods
Patient tissue DNA collection
For the present study, we used fresh-frozen brain samples from
16 semantic dementia patients with confirmed FTD-TDP type C
pathology, obtained from the Netherlands Brain Bank (Table 1)
(Mackenzie and Neumann, 2017). Informed consent was
obtained from all patients for brain autopsy and the use of tis-
sue and clinical information for research purposes. DNA was
extracted from fresh frozen brain samples of middle temporal
gyrus (n = 14) and from the dentate gyrus (n = 13). From all
cases, DNA from blood was available, obtained during life in
12 patients from the Dutch FTD study and extracted from
blood obtained at the time of autopsy in the remaining four
cases (Seelaar et al., 2008, 2011). The average age at death was
69 (range 62–74), 50% of patients were female. Medical
records and neuroimaging (either CT or MRI) were collected
and reviewed, if available. For 14 patients the left hemisphere of
the brain was fresh-frozen for research, versus the right hemi-
sphere for two patients.
Whole exome sequencing
Blood-derived DNA of 16 patients and brain-derived DNA
from middle temporal gyrus (n = 14) and/or dentate gyrus
(n = 13) of semantic dementia brains (n = 16) was captured
using Nimblegen’s SeqCap or MedExome library prep kits and
sequenced to an average depth of 139 , 496 and 395 , re-
spectively. Reads were mapped to the hg19 reference genome
using BWA and processed using picard and GATK, following
best practices. Candidate variants were called using thresholds
to detect variants present in the brain (45 reads), but absent in
blood (41 read). The next three filtering steps for candidate
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variants were; (i) a custom signal to noise filter (S2N 55) as
described in the Supplementary material; (ii) a minor allele fre-
quency 5 0.01% in the ExAC database; and (iii) a CADD score
above 10.
Validation amplicon panel
sequencing
We validated a selection of candidate variants (present in brain,
absent in blood) to confirm true-positive variants, and two can-
didate genes (GRN and TARDBP) to exclude false negatives,
by amplicon panel sequencing of the same DNA samples used
in the discovery whole exome sequencing. All candidate variants
in these targets were included in a custom amplicon panel
(SWIFT, product code SW CP-ER6161) and sequenced to an
average depth of 1601 on a MiSeq v3 with 600 cycles. A se-
cond round of amplicon panel sequencing was carried out for
further classification of somatic variants of interest in DNA
from additional cortex regions (middle frontal gyrus, superior
parietal lobe) and cerebellum of two semantic dementia brains,
and in DNA from middle temporal gyrus of 66 non-demented
control brains from the Netherlands Brain Bank. Data analysis
of the panel was done similar to the discovery. Candidate som-
atic variants were validated when: (i) read depth in the valid-
ation was at least 100; (ii) the variant allele count was at least
20 in DNA of the brain; (iii) the variant allele frequency was at
least 1% in DNA of the brain; and (iv) variant allele frequency
was 51% in blood of the same patient.
Validation of TARDBP variants
We performed additional validation using digital droplet PCR
of two TARDBP somatic variant carriers. In short, custom
LNA FAM + HEX probes for each variant were designed and
optimized by TATAA Biocenter. Synthetic DNA fragments
(gBlocksTM) with these variants were generated to serve as posi-
tive controls and as a dilution ladder for technical evaluation of
the assay. Negative controls were water and DNA of middle
temporal gyrus from two unrelated non-demented controls.
Each assay was tested on five brain regions of the carrier (med-
ial temporal gyrus, medial frontal gyrus, superior parietal gyrus,
dentate gyrus and cerebellum), blood and the two negative con-
trols. Droplets were generated using Bio-Rad’s Droplet
Generation Oil for Probes (cat#1863005) in combination with
the qPCR Droplet PCR supermix (no dUTP, Bio-Rad
cat#1863024) on a Bio-Rad QX200 Droplet Generator. The
PCR plate was measured using the QX200 Droplet Reader
(Bio-Rad) and analysed with the Quantasoft Analysis Pro soft-
ware (Bio-Rad). Reactions with fewer than 10 000 accepted
droplets were not used in the analysis. Sensitivity rates of the
assays were established using 0.1%, 1.0% and 2.5% spiked
positive control gBlocksTM mutation fragments and subsequent-
ly used to estimated variant allele frequencies by the ratio of
FAM-positive droplets over HEX-positive droplets.
Germline variants in blood and
brain
To exclude (de novo) germline variants in 12 FTD (CHMP2B,
DPP6, FUS, GRN, MAPT, OPTN, SQSTM1, TARDBP,
TBK1, TREM2, UNC13A and VCP) candidate genes we per-
formed regular germline variant calling using GATK’s
Haplotypecaller using best practices (van Rooij et al., 2017;
Ferrari et al., 2019; Greaves and Rohrer, 2019; Clarimon et al.,
2020). Variants were annotated using annovar and were manu-
ally evaluated based on exonic function, CADD score, frequency
in GnomAD, variant allele frequency and presence in the other
tissues of the same patient.
Table1 Patient characteristics
Patient Sex Age at onset Disease
duration
Dominant
side
pathology
Brain tissue
side
Dominant side MTG DG
SD01 Female 60 10 Both Left No Yes No
SD02 Male 48 14 Left Left Yes No Yes
SD03 Female 60 8 Both Left NA Yes No
SD04 Female 45 20 Both Left NA Yes Yes
SD05 Male 56 10 Both Left No Yes Yes
SD06 Male 51 12 Both Left No Yes Yes
SD07 Female 53 11 Both Left No No Yes
SD08 Male 57 12 Left Left Yes Yes Yes
SD09 Female 63 11 Both Left NA Yes Yes
SD10 Male 55 13 Left Right No Yes Yes
SD11 Male 51 15 Both Left No Yes Yes
SD12 Female 60 12 Both Left No Yes Yes
SD13 Female 63 9 Left Right No Yes Yes
SD14 Male 57 15 Both Left No Yes Yes
SD15 Female 66 8 Left Left Yes Yes No
SD16 Male 61 13 Both Left Yes Yes Yes
Contains clinical and pathological information on the patients examined in this study. Pathological diagnosis, as extracted from the reports from the Netherlands Brain Bank. The
most affected side of the brain is reported according to the post-mortem pathological examination. Brain tissue side: the side of the brain fresh frozen and used in this study.
Dominant side yes/no; whether the side studied was the one most affected according to neuroimaging (NA = not applicable, as both sides were equally affected). Middle temporal
gyrus (MTG) and dentate gyrus (DG) indicate whether these areas were available and included in the study.
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Functional analysis of somatic
TARDBP variants
The functional impact of both somatic TARDBP variants on
the TDP-43 protein was assessed by a previously published add-
back splicing assay and by immunofluorescent microscopy of
TDP-43 in HeLa cells (D’Ambrogio et al., 2009). In short, the
splicing assay contains a minigene construct containing CFTR
exon 9 carrying a mutation (C155T) in an exonic splicing en-
hancer sequence in order to have a 50% chance of in- or out-
splicing of exon 9. Using wild-type TDP-43 as positive control,
and complete loss-of-function F4L mutated TDP-43 as negative
control, the relative impact of L41F and R42H on TDP-43 func-
tion could be ascertained. To obtain P-values, an unpaired t-test
was carried out using GraphPad software (GraphPad Software,
La Jolla California, USA). For the immunofluorescence assays,
HeLa cells were transfected with wild-type TDP-43 or with
TDP-43 carrying variants L41F or R42H. Nuclei were located
by chromatic staining of DAPI, and co-localization of TDP-43 is
identified by FLAG-TDP-43 protein, as published previously
(Mompean et al., 2017). FLAG TDP-43 staining was quantified
using regions of interest for nuclear and cytoplasmic signal using
Fiji ImageJ software. The percentage of nuclear and cytoplasmic
fluorescent signal was measured for nine cells each for the wild-
type, L41F and R42H TDP-43 expressing cells. Statistical tests
were performed using two-way ANOVA in GraphPad for nu-
clear-cytoplasmic TDP-43 localization within each cell-line, as
well as between the wild-type and the L41F or R42H TDP-43
transfected cells.
Cell-type specificity of the somatic
R42H TARDBP variant
For the R42H TARDBP variant carrier, we performed fluores-
cence-activated nuclear sorting (FANS) on the frontal lobe and
parietal lobe, then isolated DNA from the nuclei with QIAamp
DNA Micro Kit (QIAGEN). Using NeuN and Olig2 as cell sur-
face markers, we separated neurons (NeuN-positive) and oligo-
dendrocytes (Olig2-positive) from microglia, astrocytes and any
other nuclei (double negative). Parietal cortex tissue from a de-
mentia patient unrelated to this study was similarly sorted and
used as negative control. Each resulting DNA sample was
amplicon sequenced and analysed using the described
procedures.
Data availability
All main results are available through Tables 1, 2 and
Supplementary Tables 1–3. Additional data from the raw results
are available on request from the authors.
Results
Deep whole exome sequencing
All DNA samples from middle temporal gyrus (n = 14), den-
tate gyrus (n = 13) and blood (n = 16) were sequenced to an
average depth of 496 (range 429–658), 395 (range 310–
520) and 139 (range 72–229), respectively.
Exclusion of causal germline
variants
Germline variant analysis in the whole exome sequencing
data of all semantic dementia patients did not result in
known pathogenic variants in any of the 12 known FTD
genes. One patient was identified as germline carrier of the
V90A variant in TARDBP, which was also reported in con-
trols and thus considered of uncertain significance
(Supplementary Table 1) (Borroni et al., 2010; Lattante
et al., 2013; Caroppo et al., 2016).
Discovery and validation of somatic
variants in semantic dementia
brains
After signal to noise, minor allele frequency and CADD
score filtering we retained on average 172 variants for den-
tate gyrus and 57 for middle temporal gyrus per patient
(Fig. 1 and Supplementary Fig. 1). We detected variants in
1450 genes from the dentate gyrus and/or middle temporal
gyrus of at least one semantic dementia patient and absent
in blood. To confirm true-positive variants, we selected a set
of 305 variants for validation in a panel of amplicon
sequencing based on one of the two following criteria:
(i) somatic variants present in at least five brains (resulting
in 252 variants in a total of 128 genes); or (ii) variants in
candidate genes involved in neurodevelopmental or neurode-
generative diseases (resulting in 53 variants in 51 genes pre-
sent in one to four brains). Amongst the 51 candidate genes
fulfilling the second criterion were single variant carriers in
TARDBP (R42H) and in GRN.
We identified eight true-positive variants in the panel of
amplicon sequencing (5100 depth in both brain and
blood, variant observed 520 times in the brain, variant al-
lele frequency of 51% in brain and 41% in blood). Seven
of those were previously detected with exome sequencing,
whereas the eighth variant was not detected in exome
sequencing but identified though rescreening of the
TARDBP gene in the amplicon sequencing data (Table 2).
The non-synonymous variant (R42H) in TARDBP;
chr1:11073909-G/A with a CADD score of 20 was the most
significantly replicated variant (271 of 18 990 sequenced
fragments in middle temporal gyrus, and none of 5126 frag-
ments in blood) and completely absent from gnomAD (vari-
ant allele frequency of 1.4% in the middle temporal gyrus of
a single semantic dementia brain).
A second non-synonymous variant in the same exon;
chr1:11073905-C/T (L41F) in the TARDBP gene was
detected in the dentate gyrus of another patient with variant
allele frequency of 2.0% in the amplicon panel sequencing
data [152 of 7533 fragments, P = 2.8  10–47, odds ratio
(OR) = 47, 95% confidence interval (CI) = 18–175, com-
pared to blood]. This variant with a CADD score of 28 was
also absent from the population databases, and was not
observed in blood-derived DNA or any of other brain
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regions of the same patient (Fig. 2). Both variants observed
in a single patient each were taken forward for further valid-
ation by digital PCR and functional testing, as germline var-
iants in TARDBP are known to cause FTD and/or
amyotrophic lateral sclerosis with TDP-43 pathology
(Borroni et al., 2010; Lattante et al., 2013; Caroppo et al.,
2016).
Validation of TARDBP variant R42H
by amplicon sequencing, digital
droplet PCR
After confirming presence of this variant in middle temporal
gyrus (271 fragments of 18 990, P = 8.9  10–29) and ab-
sence in 5123 sequenced fragments from blood, we validated
this variant in other cortical regions of the same brain. We
observed this variant with similar frequency in the parietal
lobe (1.2%, 12 of 973 fragments, P = 2.3  10–10), in the
frontal lobe (0.5%, 11 of 2,122 fragments, P = 1.3  10–6),
and at lower frequency in the hippocampus (0.3%, 8 of
3021 fragments, P = 3.6  10–4) and cerebellum (0.1%, 3 of
2881 fragments, P = 4.7  10–2), although the variant allele
frequency observed in hippocampus and cerebellum were
within the range observed in the other samples, as shown in
Fig. 2A. The variant was not observed among temporal cor-
tex samples of 66 non-demented controls (0.03%, total 28
fragments of 106 635, likely representing random sequenc-
ing errors). The R42H variant was then sequenced in only
neuronal nuclei (NeuN-positive), oligodendrocyte nuclei
(Olig2-positive) or the nuclear fraction containing, amongst
others, astrocytes and microglia (and other NeuN/Olig2
double negative CNS cell nuclei) in both frontal and parietal
lobe of the R42H carrier to an average depth of 3579 .
The R42H variant was detected in 2.4% of the neurons in
the parietal lobe and 1.1% in the frontal lobe (74 and 42
fragments of 3093 and 3806 in total, respectively). These
frequencies were doubled compared the bulk parietal and
frontal tissue (1.2% and 0.5%, respectively). The variant
was not observed in the control sample (50.1%) and at
three to four times lower frequencies in the oligodendrocytes
or double negative nuclear fraction (50.5% in the parietal
lobe and 50.4% in the frontal lobe, respectively).
Validation using digital droplet PCR confirmed the ampli-
con sequencing results, as shown by the allelic discrimin-
ation plots (Fig. 3). The variant was observed in 242
droplets of 13 048 non-empty droplets (variant allele fre-
quency = 1.9%) in the temporal lobe which was significant-
ly higher than the negative controls; blood of the same
patient (variant allele frequency = 0.1%, 1 of 809 droplets,
P = 1.1  10–5) and temporal lobe of two non-demented
controls (variant allele frequency = 0.04%, 3 of 7698 drop-
lets, P = 1.5  10–44). Similarly, the variant was observed at
significantly higher levels compared to the controls in the
frontal lobe (variant allele frequency = 1.3%, 126 droplets
of 9549, P = 6.7  10–4 and P = 1.1  10–28) and parietal
lobe (variant allele frequency = 0.6%, 21 of 3697 droplets,T
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P = 0.16 and P = 3.5  10–8) and cerebellum (variant allele
frequency = 0.1%, 13 of 9231 droplets P = 1.0 and
P = 0.04).
Validation of TARDBP variant L41F
by amplicon sequencing, digital
droplet PCR
The second TARDBP somatic variant in the same exon was
detected in the dentate gyrus with a variant allele frequency
of 2.0% in the amplicon panel sequencing data (152 of
7533 fragments, P = 2.8  10–47) compared to blood
(Fig. 2B). The variant was not observed among temporal
cortex samples of 66 non-demented controls (0.04%, total
39 fragments of 106 632, likely representing random
sequencing errors). Validation with digital droplet PCR con-
firmed absence of the variant in blood, cerebellum, frontal
lobe, temporal lobe and parietal lobe. Because of the low
quantity of DNA from laser-capture microdissection-derived
dentate gyrus, this tissue could not be tested using digital
PCR. This may have also influenced the whole exome
sequencing (WES) result, in which many PCR duplicates
were observed for the dentate gyrus data. We did not find
any other somatic variants in the TARDBP gene in any of
the other semantic dementia brains (average coverage across
the gene of 1116) and also not in middle temporal gyrus of
non-demented control samples (average coverage of 103
across the gene).
Clinicopathological description of
the two cases with somatic TARDBP
variants
Both patients carrying the TARDBP L41F or R42H somatic
variant developed progressive problems with word finding
and language comprehension, and visual agnosia at the age
of 55 and 57, respectively. Compulsive-obsessive behaviour,
loss of initiative and emotional lability were salient features
Figure 1 Flowchart of data filtering and analysis. From top left: Raw somatic variant calling using blood and dentate gyrus (DG) or medial
temporal gyrus (MTG) deep exome sequencing data (WES), signal to noise filter (S2N), minor allele frequency filter (MAF), CADD score filter,
annotating and grouping per gene, resulting in the genes affected in each patient with semantic dementia (SD). Right: Grouping genes affecting mul-
tiple patients (45) or affecting candidate genes in fewer patients (one to four) to be included in the validation amplicon panel. To excluded false
negative findings in the WES data in FTD-TDP known germline causal genes GRN and TARDBP, all exons in these genes were included in the valid-
ation panel. The first validation round was performed on the same tissues as the discovery WES to confirm true positive variants from the WES, or
identify false negative findings in GRN or TARDBP. The second round of validation further classified true positive variants in additional brain tissues
and non-demented controls.
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in both patients, similar to the other 14 patients. Profound
left-sided temporal atrophy was observed by neuroimaging
(CT, MRI) 2 and 3 years after onset in both TARDBP car-
riers, in contrast to asymmetric but bilateral atrophy in the
other semantic dementia patients (Fig. 4). Neuropathological
examination after death (68 and 72 years, respectively)
showed severe anterior temporal atrophy, left more pro-
nounced than right in the L41F carrier and more symmetric-
al in R42H. Microscopically, neuropathological changes
were consistent with TDP-pathology type C, with severe
neuron loss, gliosis in the temporal cortex with long thick
threads and round cytoplasmic inclusions in granular cells of
the hippocampus. For the L41F carrier, DNA of the middle
temporal gyrus from the right hemisphere was available in
the Netherlands Brain Bank and used for all DNA analyses,
for the carrier of the R42H variant this was the middle tem-
poral gyrus of the left hemisphere.
Functional analysis of TARDBP
variants
TDP-43 (encoded by TARDBP) is a protein involved in
RNA splicing (Buratti and Baralle, 2001; D’Ambrogio et al.,
2009). Therefore, the impact of both TARDBP variants on
the activity and localization TDP-43 was established in two
assays; splicing regulation and cellular localization. The
splicing assay contains a minigene construct containing
CFTR exon 9 carrying a mutation (C155T) in an exonic
splicing enhancer sequence in order to have 50% chance
of in- or out-splicing of exon 9. The splicing is mediated by
TDP-43 binding to the UG-repeat sequences near the 30 start
site. Thus, when the function of TDP-43 is lost upon tar-
geted small interfering RNA (siRNA) treatment, a decrease
to 20% of exon 9 skipping is observed. Exon 9 skipping is
then rescued by adding back wild-type TDP-43 whose tran-
script has been made resistant to siRNA treatment. As nega-
tive control, we used a construct containing a TDP-43 that
carries variant F4L, which is also resistant to the siRNA
treatment but cannot bind RNA (Buratti and Baralle, 2001).
In the presence of these positive and negative controls, the
impact of uncharacterized TDP-43 variants can then be eval-
uated by comparing the amount of exon 9 skipping of each
expressed variant. Both variants significantly decreased
exon 9 skipping compared to wild-type TDP-43, as shown
in Fig. 5. Splicing impairment was stronger for the L41F
variant than for the R42H variant, in accordance with the
predicted impact with CADD scores of 28 and 20, respect-
ively. The impact on TDP-43 function was smaller for both
Figure 2 Allele frequencies for L41F and R42H in all tested amplicon panel samples. Each column is a sample, the tissues repre-
sented by colour; blood (BL, blue), cerebellum (CER, green), dentate gyrus (DG, red), hippocampus (HIP, orange), middle temporal gyrus (MTG,
purple), middle frontal gyrus (MFG, salmon) and superior parietal lobe (LPS, pink). The vertical axis shows the variant allele frequency in that re-
spective tissue, with lines representing the 0.25% and 0.50% thresholds. The tissues with highest variant allele frequency are labelled with the pa-
tient identifier and respective tissue.
Somatic variants cause semantic dementia BRAIN 2020: 143; 3827–3841 | 3833
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article/143/12/3827/5957446 by guest on 12 February 2021
variants compared to the siRNA-resistant TDP-43 variant
F4L, which blocks RNA binding completely.
Immunofluorescent staining demonstrated significantly
altered localization of the R42H mutant TDP-43 protein
compared to wild-type TDP-43 (Fig. 6). In the wild-type
cells, 78% of the fluorescent signal was nuclear (n = 9), ver-
sus 71% for the L41F cells (P = 0.54) and 52% for the
R42H cells (P = 0.0004). Only in the R42H TDP-43
expressing cells was TDP-43 no longer significantly localized
in nuclei compared to cytoplasm. Region of interest meas-
urements and statistical results are provided in
Supplementary Table 2.
Discussion
The present study identified the occurrence of two low-level
pathogenic somatic variants in the TARDBP gene in brains
of patients with semantic dementia. These two variants in
the first exon of the gene are absent from public databases
and significantly affect TDP-43 function and localization.
Moreover, the temporal lobe atrophy observed by MRI
neuroimaging 3 years after onset in one of the two somatic
TARDBP variant carriers resembled classical FTD due to
germline TARDBP variants.
The observed low level (1–3%) of TARDBP somatic var-
iants in brain-derived DNA was in accordance with the hy-
pothesis that somatic variants occurred in one or more
clones of neurons acquired in a single neural progenitor cells
during brain development. Subsequently, the pathophysio-
logical process arising from neurons carrying the somatic
variants would then result in focal neurodegeneration later
in life. The low percentage may further be attributed to by
selective loss of neurons that carried the somatic variants in
the affected brain region. The presence of somatic variants
shared by (a) clone(s) of neurons in the temporal cortex or
dentate gyrus was in contrast to recent studies, which inves-
tigated post-mitotic somatic mosaicism (pathogenic single-
nucleotide variants and somatic copy-number variations) of
known germline disease genes in individual cells (Lee et al.,
2018; Lodato et al., 2018; Mokretar et al., 2018). Such
post-mitotic somatic variants increased with age in the latter
studies and were found in significantly higher number in
Figure 3 Allelic discrimination plots of the digital droplet PCR for the R42H TARDBP somatic variant. Each marker represents a
single droplet and its respective wild-type (horizontal axis) and variant (vertical axis) signal intensity. Five different tissues of the carrier were
tested: blood, middle temporal gyrus (MTG), middle frontal gyrus (MFG), lateral parietal lobe (LPS), cerebellum (CER) and a negative control of
water is shown. The grey droplets are considered empty, green droplets are wild-type only, orange is both wild-type and variant alleles, and blue
droplets were harbouring only the variant allele.
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Alzheimer’s disease or Parkinson’s disease brains compared
to controls (Lee et al., 2018; Lodato et al., 2018; Mokretar
et al., 2018). Although these somatic DNA variations for
age-associated brain diseases were potential interesting, their
causal role could not be determined for sure (Lodato et al.,
2018).
Post-mitotic variants are a less likely cause for semantic
dementia in patients as the disease occurs at a relatively
young onset age (565 years) and its prevalence does not in-
crease with age (Hodges et al., 2010; Landin-Romero et al.,
2016). Therefore, our sequencing of DNA from bulk tissue,
aiming to identify variants shared by neurons, and estimat-
ing their variant-allele-frequencies resembled the study of
Park et al. (2019) in which somatic variants were found per
brain region (hippocampal formation) in both Alzheimer’s
disease patients and controls.
The presence of single somatic variants (R42H and L41F)
in the TARDBP gene in several neocortical regions (tem-
poral, frontal and parietal) or dentate gyrus strongly points
to the initial occurrence of somatic mosaicism in a single
neural progenitor cell (Zilles et al., 2013; Palomero-
Gallagher and Zilles, 2019). Somatic variants in neurons
arising from the ventricular or subventricular zone have also
been shown in childhood or adult neurological diseases (Lee
et al., 2012; Lim et al., 2015). By using blood-derived DNA
from the same patients as control tissue, we could exclude
somatic variants occurring from non-ectodermal lineages
(Leija-Salazar et al., 2018). Somatic TARDBP variants could
be excluded from 66 non-demented controls by using tem-
poral cortex-derived DNA. As the specific somatic variant
(R42H) was absent in both hippocampus and cerebellum of
the same patient, the variant must have occurred in neural
progenitor cells of the lateral segment of the pallium, which
develops into the neocortex (Zilles et al., 2013; Palomero-
Gallagher and Zilles, 2019). The variant was enriched (twice
as frequent compared to bulk cells) in the neuronal subpo-
pulation of the parietal and frontal lobes, further suggesting
the neural origin. A low signal (520% of signal in the neur-
onal fraction) of the variant in the other nuclear fractions is
a likely due to some residual neuronal nuclei present in the
NeuN-negative fraction. Based on these results, we estimate
that the R42H variant is present in 5.6%, 4.8% and 2.2%
of the neurons in the temporal, parietal and frontal lobes, re-
spectively. The second variant (L41F) was only detected in
the hippocampus, suggesting that it occurred in neural pro-
genitor cells of the medial segment of the pallium. The asym-
metric onset of the disease pathology in these cases did not
necessarily require the occurrence of the somatic variants
after developmental separation of both hemispheres, as
germline variants have also been associated with other asym-
metric neurodegenerative disease processes (Stiles and
Jernigan, 2010; Caroppo et al., 2016; Gonzalez-Sanchez
et al., 2018). Although of interest, due to the collection pro-
cedure in the Netherlands Brain Bank, freezing only one
hemisphere, the occurrence of absence of the variants in the
other hemisphere could not be tested. The similarity in clin-
ical and pathological phenotype (i.e. severe temporal atro-
phy, TDP-43-positive inclusions) between the somatic
TARDBP variant carriers and germline TARDBP variant
carriers supports the potential pathogenicity of these variants
(Caroppo et al., 2016; Gonzalez-Sanchez et al., 2018).
Both TARDBP variants identified (L41F and R42H) are
located in the first exon of TARDBP and are non-synonym-
ous changes predicted to impact the N-terminal domain of
Figure 4 Axial T1-weighted MRI of the semantic dementia patient carrying somatic variant R42H, showing profound leftsided
temporal atrophy 3 years after disease onset. Pathological examination 15 years after disease onset showed atrophy of both temporal
poles. The middle image is from a patient without a somatic variant (4 years after onset) showing atrophy of both temporal lobes. Right: A patient
with the germline (p.I383V) TARDBP variant, showing a similar atrophy pattern bilaterally (4 years after onset).
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Figure 5 Impact of both TARDBP variants on the splicing regulation functionality of TDP-43, demonstrated by splice-in/out
add-back assay of CFTR exon 9. From left to right: The first two lanes show the baseline measurement with both splicing in and out of exon 9
in the absence (-) or presence of TDP-43 siRNA (+). Lane 3 shows that addition of si-resistant wild-type TDP-43 can rescue the splicing function-
ality (WT) but this cannot be achieved by a TDP-43 carrying the F4L mutation that does not allow the protein to bind RNA (lane 4). Lanes 5 and
6 show the results obtained after the addition of mutated TDP-43 carrying the predicted damaging variants (R42H and L41F). Middle: Western
blots showing equal expression of the flagged-TDP-43 wild-type and mutants (pFlag-TDP-43s) following knockdown of the endogenous protein
(end. TDP-43). Tubulin was used as an internal control. Bottom: Quantification of the ratio of CFTR exon 9 inclusion. The standard deviation and
P-values are reported for three independent experiments. Unpaired t-test was performed for statistical analysis (*P5 0.05).
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Figure 6 Impact of TARDBP variants on the localization of flagged-TDP-43 wild-type and mutant proteins overexpressed in
HeLa cells. The overexpressed proteins were visualized using anti-Flag polyclonal antibody in a 100 nm/pixel field. Scale bar = 10 nm. Top row:
Wild-type Flag TDP-43, followed by Flagged TDP-43s carrying both variants; L41F and R42H. Left column: DAPI staining to indicate the chromatin
in the nucleus in blue. Middle column: TDP-43 stained in red with a Flag-specific antibody. Right column: Merged images demonstrating TDP-43 lo-
calization in the nucleus for wild-type TDP-43, whilst localizing also in the cytoplasm for both TDP43 with variant R42H and L41F. Bottom: Box
plots showing fluorescent TDP-43 signal is quantified in the nucleus and cytoplasm for nine cells of each line. The average ratio of nuclear and
cytosolic signal is plotted and compared between groups. ****P5 0.0001 and ***P5 0.001 as calculated by two-way ANOVAs between the
groups illustrated.
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the protein with CADD scores of 28 and 20, respectively
(Chang et al., 2012; Zhang et al., 2013; Sasaguri et al.,
2016). Both variants are absent in human germline popula-
tion databases ExAC and gnomAD; in fact, only eight germ-
line variants in the first exon of TARDBP (amino acids 1–
79) are described in the gnomAD database (120 000 partici-
pants), all extremely rare (50.003%, 20 carriers across all
eight variants combined). Our findings, identifying somatic
variants in the N-terminal domain (amino acids 41 and 42)
of TARDBP, are in contrast with all germline TARDBP
gene variants for familial amyotrophic lateral sclerosis, and
occasionally for familial FTD, reported in the glycine-rich re-
gion (GRR domain) between amino acids 262 and 414 of
the TDP-43 protein (Barmada and Finkbeiner, 2010;
Borroni et al., 2010; Lattante et al., 2013; Caroppo et al.,
2016; Wang et al., 2016).
Our functional assays convincingly demonstrate a disrup-
tive effect of both variants on normal TARDBP protein
function. The impact on TDP-43 activity via CFTR minigene
splicing was stronger for L41F than for R42H, with 75%
and 40% decrease of TDP-43 activity, respectively, com-
pared to wild-type (D’Ambrogio et al., 2009; Mompean
et al., 2017). Also, the redistribution of mutant TDP-43 in
HeLa cells, from mostly nuclear in unaffected control to
both cytoplasmic and nuclear for the R42H variants, sup-
ports the cellular pathogenicity. Together, both assays sug-
gest that a correctly folded N-terminal domain of TDP-43 is
required for nuclear localization and function, and that neu-
rons carrying these somatic variants have dysfunctional
TDP-43 and redistribution of TDP-43 protein to the cyto-
plasm as observed in FTD and amyotrophic lateral sclerosis
brains (Chang et al., 2012; Ihara et al., 2013; Zhang et al.,
2013; Qin et al., 2014; Romano et al., 2015; Sasaguri et al.,
2016; Mompean et al., 2017; Weskamp and Barmada,
2018). The resulting impact on TDP-43 function in shuttling
RNA from the nucleus to the cytoplasm might lead to the
protein aggregates observed in semantic dementia brains and
subsequent pathogenicity for the cells and tissue in which
the variants are present (Barmada and Finkbeiner, 2010;
Igaz et al., 2011).
It is unclear how dysfunction of a small percentage of
affected neurons (2–6%, double the variant allele frequency)
would lead or contribute to extensive degeneration of the
temporal lobe and widespread pathology (10–15% of neu-
rons) in the dentate gyrus. Potentially, neuronal dysfunction
within one brain region can accumulate until neuron-neuron
signalling is sufficiently impaired to functionally disrupt the
entire region. Another consideration is that the current study
consider mosaicism in bulk DNA of all neurons in the tem-
poral lobe and/or dentate gyrus, whereas many subtypes of
neurons exist in these regions, leaving the possibility that the
small number of affected neurons in these patients are
enriched for a specific neuronal subtype. In Alzheimer’s dis-
ease, for instance, a selective loss of parvalbumin-positive
GABAergic interneurons (3% of the total neuronal popu-
lation) has been observed (Brady and Mufson, 1997), and
the selective dysfunction of these neurons has been causally
linked to global brain network changes and progressive
amyloid pathology (Verret et al., 2012; Iaccarino et al.,
2016; Hijazi et al., 2019), indicating that small populations
of affected neurons can indeed contribute to more wide-
spread neurodegenerative processes. The challenges in inter-
preting selective neuronal dysfunction in the context of
widespread neurodegeneration are exemplary of the overall
discussion on how neurodegeneration starts and progresses
(often differently between patients) throughout the brain, re-
gardless of initial cause of the disease. Further work is
needed to fully understand these processes and place the
contribution of developmental and post-mitotic somatic
DNA variation in the context of disrupted brain function.
Cell-specific studies of semantic dementia brains carrying
these somatic TARDBP variants may determine in which
neuronal subtypes the somatic variants were present.
An important question that remains is why somatic var-
iants were not found in all 14 brains with semantic demen-
tia. There are several potential explanations, some of which
include limitations of this study: (i) the bioinformatic filter-
ing steps (absent in blood, CADD score 4 10) may have
been too stringent and removed potentially causing somatic
variants; (ii) pathogenic non-coding variants may have been
not detected by the present exome sequencing, and low-level
copy number variants missed by the present approach;
(iii) causal somatic variants may have become undetectable
(disappeared) due to neuron loss in medial temporal gyrus
during the neurodegenerative process; (iv) the disease may
have originated from causal somatic variants that were only
present in the temporal cortex or dentate gyrus opposite to
the side of the examined fresh-frozen brain samples, even
though we expected that somatic variants occurred prior to
the hemisphere separation in brain development; and
(v) multifactorial genetic or non-genetic factors may be re-
sponsible for most of the semantic dementia cases. Finally, we
may have overlooked a relevant variant in the WES data by
first focusing on shared variants or damaging variants in can-
didate genes, which may be less likely true variants.
Additionally, the low-level (50.5%) error rate of the sequenc-
ing requires stringent filtering, which may exclude variants
that could be detected through panel sequencing, and further
investigation of the data may uncover additional relevant var-
iants, as was observed for the L41F variant. Pathogenicity of
the remaining six variants confirmed by panel sequencing val-
idation must be validated by future studies.
An interesting issue is whether somatic variants present in
TDP-43 related genes may trigger dysregulation in the TDP-
43 pathway. In analogy to this, Park et al. (2019) reported
a significant enrichment of somatic variants in the PI3K-
AKT, MAPK and AMPK pathways in Alzheimer’s disease
brains versus control brains. Using a KEGG pathway over-
representation analysis, they hypothesized that multiple dis-
ease-causing somatic variants converge onto pathways that
potentially affect tau phosphorylation. In our view, the next
step would be to perform amplicon panel sequencing of a
set of FTD-TDP related genes on both semantic dementia
brains and controls in order to detect potential additional
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causal somatic variants in the TDP-43 pathway. Moreover,
investigating other series of semantic dementia brains may
support our findings, and may give a better estimation of
their frequency in semantic dementia. Finally, the present
findings raise the question whether somatic variants may be
causative in other types of FTD, for example somatic var-
iants in MAPT causing sporadic Pick’s disease. Overall, it
seems warranted to carry out such targeted deep sequencing
in all well-defined dementia subtypes.
Finally, although our unbiased deep sequencing approach
yielded a substantial number of false-positive variants, des-
pite extensive efforts to identify the most likely true variants,
it also resulted in the detection of true-positive variants in a
well-known candidate gene causative for FTD with TDP-43
pathology. In our view, future studies may choose between
two alternative approaches: (i) targeted deep sequencing of
bulk tissue of a large number of candidate genes in one way
or another related to the pathophysiology; or (ii) single-cell
whole genome sequencing generating more reliable data on
true-positive variants.
In conclusion, low-level somatic pathogenic variants in the
TARDBP gene are an underlying genetic cause of non-famil-
ial semantic dementia. This phenomenon needs investigation
in other cases of semantic dementia, as well as in other
early-onset neurodegenerative diseases, for example non-fa-
milial FTD with tau pathology. Moreover, in other neurode-
generative diseases, such as Alzheimer’s disease or
Parkinson’s disease, somatic variants may also play a causal
or contributing role, and deserve further investigation.
Further investigation of somatic variants in known disease
genes is warranted, specifically in patients without positive
family history and with clearly defined focal neurodegenera-
tion. Our findings have implications for understanding of
neurodegenerative disease and the specific role of germline
versus somatic variants therein. Also, negative germline vari-
ant testing might be insufficient for some diseases, and may
require DNA from the appropriate tissue instead to detect
somatic variants in order to determine disease causes.
Finally, studying the properties of somatic disease-causing
genetic variants may reveal novel underlying disease proc-
esses and point towards new therapeutic strategies.
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